Search results

Hypertension and nephrology

AUGUST 20, 2018

[Significance of patient adherence in the treatment of hypertension]

SIMONYI Gábor, ALFÖLDI Sándor, BARNA István

[Hypertension is the one of most frequent chronic disease which a major but modifiable cardiovascular risk factor. In treating of hypertension after life style therapy, drug treatment has an essential role. Patient adherence plays a significant role achieving target blood pressure. One of most important cause of resistant hypertension is the non-adherence. Factors influencing adherence include the number of drugs, their daily dosage frequency, the properties of the drug groups used, age and gender too. According to international and domestic studies, the number of people leaving medication is very high. The disadvantage is clear because these patients lack of benefit from the protective effects of drugs.]

Hypertension and nephrology

AUGUST 20, 2018

[Patient-practitioner cooperation - medication adherence and persistence in the CONADPER-HU study]

SZEGEDI János, KÉKES Ede, KISS István

[Hypertension is a common popular disease, it basically determines the health status, morbidity, cardiovascular mortality, rehabilitation and quality of life of the population. Prevention, early detection, effective treatment of the disease, quality of care is an important part of the people’s health program. The success of the therapy, the attainment and long-term maintenance of the target blood pressure - in addition to many other factors - is determined by drug adherence and persistence, one of the crucial elements of which is the optimal cooperation of the physician and patient. The poor persistence causes most of the therapeutic failures. The main objective of the CONADPER-HU study was to optimize practitionerpatient cooperation (increased control, information delivery, home blood pressure measurement, telemedicinal equipements and software use), thus increasing the proportion of patients with target blood pressure and reducing the number of resistant hypertensive patients. The study proved that the complex care system is effective and has a positive impact on persistence. It has also been clarified that the first three months will decide on further sustained therapeutic success.]

Hypertension and nephrology

SEPTEMBER 12, 2018

[Treatment of hypertension in kidney transplant patients]

KOVÁCS Tibor, WAGNER László

[Most of the renal transplant recipients suffer from hypertension. Hypertension substantially contributes to the high cardiovascular mortality in this population. The recommendation of the Hungarian Society of Hypertension and the international guidelines suggest to achieve less than 130/80 mmHg as target blood pressure in these patients. Several factors may be in the background of hypertension after kidney transplantation, which can be summarized as factors from the recipient-side, the donorside and factors provoked by transplantation itself. In most of the cases early after transplantation high doses of immunosuppressive drugs (especially calcineurin inhibitors and steroids) are responsible for the increased blood pressure. There are some further special methods apart from the general recommendations which are needed during the examination of hypertension of kidney transplant patients: e.g. measurement of blood trough-level of immunosuppressive drugs, investigation of bone-mineral disorder, screening for the level and causes of anaemia, check-up of the renal graft circulation. Kidney transplant patients suffering from hypertension usually need more than two antihypertensive drugs beyond the use of non-pharmaceutical antihypertensive methods. In the early posttransplantation period calcium channel blockers are preferred antihypertensive medications, because they counterbalance the vasoconstrictive effect of calcineurin inhibitors. The administration of renin-angiotensin-aldosterone inhibitors are rather suggested after the stabilization of renal function (from the 1-3 months posttransplantation). When designing antihypertensive strategy, comorbidities and special factors should be regarded as well, especially volume overload, proteinuria, allograft function (GFR), diabetes, other cardiovascular risk factors, previous cardiovascular events. The setup of an individual therapeutical strategy is advised in view of all these factors, which is different according to the timing after transplantation: the perioperative, the early postoperative phases and from 1-3 months after transplantation have special focuses.]

Hypertension and nephrology

SEPTEMBER 12, 2018

[More than bodyguard? The ramipril/amlodipine FDC effect on their whole blood pressure spectrum]

SIMONYI Gábor, ZSUZSA Pál, GENCSIOVA Kristína, FINTA Ervin

[Hypertension is a significant cardiovascular risk factor. Effective treatment of hypertension contributes to avoiding the risk of later cardiovascular complications. Rapid access to blood pressure targets is also important in new untreated hypertensive patients. In the new ESH/ESC Hypertension Recommendation - during the initiation of antihypertensive therapy - the immediate introduction of drug combinations is explicitly recommended. In our retrospective data collection study we studied the effect of the ramipril/amlodipine fixed combination on the 24-hour brachial and central blood pressure parameters of the fresh hypertensives.]

Lege Artis Medicinae

JUNE 20, 2018

[Konzerválószer-mentes krónikus kezelés glaucomában: a cseppkezelés okozta szemfelszín-betegség elkerülése]

HOLLÓ Gábor

[Ocular surface disease is a frequently seen condition in the elderly in the general po-pulation. In glaucoma patients the glaucoma-therapy related ocular surface disease is a particularly serious and common condition with complex pathogenenesis. Pre-servatives, most commonly benzalkonium chloride, employed in intraocular pressure lowering eye drops frequently cause or worsen ocular surface disease in glaucoma. The symptoms frequently undermine both the adherence to the prescribed intraocular pressure lowering drops and the vision related quality of life. Therefore the success of long-term glaucoma care in glaucoma-therapy related ocular surface disease is reduced. The current article summarizes the main pathogenetic aspects of glaucoma-therapy related ocular surface disease, and presents how to eliminate the main causative factor and normalize the ocular surface by using completely preservative free topical medication in glaucoma. ]

Hypertension and nephrology

JUNE 10, 2018

[The Effects of Antihypertensive Therapy by Current Recommendations on Depression and Other Psychometric Parameters: Topline Results ]

KŐRÖSI Beáta, LÁSZLÓ Andrea, BATTA Dóra, LÉNÁRT Lilla, FEKETE Andrea, EÖRSI Dániel, CSEPREKÁL Orsolya, TISLÉR András, NEMCSIK-BENCZE Zsófia, GONDA Xénia, RIHMER Zoltán, NEMCSIK János

Hypertension and nephrology

JUNE 10, 2018

[Antihypertensive effect of rilmenidine focusing on the Hungarian multicenter trial VERITAS]

FARSANG Csaba, FINTA Ervin

[Summary in the antihypertensive therapy, in addition to the RAS-blockers (ACE-inhibitors or ARBs), calcium antagonists and thizid-like diuretics, other antihypertensive drugs with different mechanisms of actions, such as the imidazoline I1 receptor agonists, are beneficially used. Several international and Hungarian studies showed the results of the effects of these agents. Authors emphasize the effects of the VERITAS study showing that in hypertensive patients the imidazoline I1 receptor agonist, rilmenidine significantly decreased the office blood pressure as well as the blood pressure measured by ambulatory blood pressure monitoring (ABPM). The white-coat reaction and left ventricular hypertrophy (LVH) were also decreased. In a separate study involving hypertensive subjects rilmenidine significantly increased baroreflex sensitivity. This effect may contribute - mainly during daytime - to the antihypertensive effect. Authors summarise the most important actions of rilmenidine, and the selected publications on the results of the Hungarian and international investigations.]

Clinical Neuroscience

MAY 30, 2018

[Pharmacological and nonpharmacological treatment of insomnias with regard to sleep medicine]

FALUDI Béla, ROZGONYI Renáta

[Insomnia - one of the most prevalent sleep complain - has a great impact on the everyday life. Basically two different form of insomnia can be defined: the insomnia disorder and the co-morbid insomnias. To treat adequately determination of background pathology is essential, which is based on the help of Sleep Medicine Centers. According to the newest guidelines, the treatment of insomnia disorder is based on cognitive behavioural therapies followed by pharmaceutical intervention. In this review we provide the short description of cognitive behavioural therapies and basic principles of hypnotic drugs. Despite the availability of insomnia guidelines the huge variation of the insomnia medication can be seen in the daily practice. Due to the above mentioned reasons we summarize the good clinical practice of hypnotic drug administration for insomnia patients.]

Hypertension and nephrology

APRIL 20, 2018

[Results of ATTENTION study]

LÉGRÁDY Péter, ÁBRAHÁM György

[In the ATTENTION (Using of ARB and sTaTin basEd iNdividualized Treatments in Hungarian patients In the light Of New CV prevention guidelines) trial’s ARB arm 9996 treated hypertensive patients were enrolled. Based on the results in the medical practice, the choice of the first ARB has a significant impact on the further antihypertensive therapy. Losartan, telmisartan and valsartan are all suitable for reaching the goal blood pressure. If necessary, doctors will not change the composition but the dose or use a diuretic supplement (resistant hypertension, older age etc.). Overall a telmisartan preference was observed in the study.]

Clinical Neuroscience

MARCH 30, 2018

[Nusinersen in the treatment of spinal muscular atrophy]

SINKÓ Gabriella, KISS Zsuzsanna, BERNADETTE Kalman

[Until recently, the diagnosis of spinal muscular atrophy (SMA) has been associated with severe life-long motor disability in adults and with early death in infants. The new experimental therapeutic approaches of the last few years have become more and more promising, while nusinersen was approved for the treatment of SMA in December 2016 in the USA, and in May 2017 in Hungary. Our paper presents mechanisms and clinical benefits of this new medication, and highlights some of the other therapeutic strategies still in experimental stages.]